Effect of cathepsin K inhibitors on bone resorption

Journal of Medicinal Chemistry

Volumn 51, Issue 17, 2008, Pages 5459-5462

  Teno, Naoki ^a   Masuya, Keiichi ^a,b   Ehara, Takeru ^a   Kosaka, Takatoshi ^a   Miyake, Takahiro ^a   Irie, Osamu ^a   Hitomi, Yuko ^a   Matsuura, Naoko ^a   Umemura, Ichiro ^a   Iwasaki, Genji ^a   Fukaya, Hiroaki ^a   Toriyama, Kazuhiro ^a   Uchiyama, Noriko ^a   Nonomura, Kazuhiko ^a   Sugiyama, Ikuo ^a   Kometani, Motohiko ^a  

^a Novartis Institutes for BioMedical Research   (Japan)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

7 (2,2 DIMETHYLPROPYL) 6 (1,3 DIOXO 2,8 DIAZASPIRO[4.5]DEC 2 YLMETHYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2 CARBONITRILE; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; MALE; MONKEY; NONHUMAN; OSTEOLYSIS; RAT;

ANIMALS; BONE MARROW; BONE RESORPTION; CATHEPSINS; COLLAGEN TYPE I; CYSTEINE PROTEINASE INHIBITORS; HAPLORHINI; PYRIMIDINES; PYRROLES; RATS; SPIRO COMPOUNDS; TISSUE DISTRIBUTION;

EID: 51849157339     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800626a     Document Type: Article

References (19)

1. Turk, V.; Turk, B.; Guncar, G.; Turk, D.; Kos, J. Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv. Enzyme Regul. 2002, 42, 285-303.
2. Saftig, P.; Hunziker, E.; Wehmeyer, O.; Jones, S.; Boyde, A.; Rommerskirch, W.; Moritz, J. D.; Schu, P.; von Figura, K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13453-13458.
3. Gelb, B. D.; Shi, G.-P.; Chapman, H. A.; Desnick, R. J. Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency. Science 1996, 273, 1236-1238.
4. Inui, T.; Ishibashi, O.; Inaoka, T.; Origane, Y.; Kumegawa, M.; Kokubo, T.; Yamamura, T. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J. Biol. Chem. 1997, 272, 8109-8112.
5. Garnero, P.; Borel, O.; Byrjalsen, I.; Ferreras, M.; Drake, F. H.; McQueney, M. S.; Foged, N. T.; Delmas, P. D.; Delaissé, J-M. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. 1998, 273, 32347-32352.
6. Grabowska, U. B.; Chambers, T. J.; Shiroo, M. Recent developments in cathepsin K inhibitor design. Curr. Opin. Drug Discovery Dev. 2005, 8, 619-630.
7. Altmann, E.; Cowan-Jacob, S. W.; Missbach, M. Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K. J. Med. Chem. 2004, 47, 5833-5836.
8. Teno, N.; Irie, O.; Miyake, T.; Gohda, K.; Horiuchi, M.; Tada, S.; Nonomura, K.; Kometani, M.; Iwasaki, G.; Betschart, C. New chemotypes for cathepsin K inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 2599-2603.
9. Altmann, E.; Aichholz, R.; Betschart, C.; Buhl, T.; Green, J.; Irie, O.; Teno, N.; Lattmann, R.; Tintelnot.Blomley, M.; Missbach, M. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J. Med. Chem. 2007, 50, 591-594.
10. Teno, N.; Miyake, T.; Ehara, T.; Irie, O.; Sakaki, J.; Ohmori, O.; Gunji, H.; Matsuura, N.; Masuya, K.; Hitomi, Y.; Nonomura, K.; Horiuchi, M.; Gohda, K.; Iwasaki, A.; Umemura, I.; Tada, S.; Kometani, M.; Iwasaki, G.; Cowan-Jacob, S. W.; Missbach, M.; Lattmann, R.; Betschart, C. Novel scaffold for cathepsin K inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 6096-6100.
11. Betschart, C.; Hayakawa, K.; Irie, O.; Sakaki, J.; Iwasaki, G.; Lattmann, R.; Missbach, M.; Teno, N. Pyrroloptrimidines as agents for the cystein proteases. World Patent WO2003020721, 2003.
12. Bleicher, K. H.; Wüthrich, Y.; DeBoni, M.; Kolczewski, S.; Hoffmann, T.; Sleight, A. J. Parallel solution- and solid-phase synthesis of spirohydantoin derivatives as neurokinin-1 receptor ligands. Bioorg. Med. Chem. Lett. 2002, 12, 2519-2522.
13. Elliott, J. M.; Broughton, H.; Cascieri, M. A.; Chicchi, G.; Huscroft, I. T.; Kurtz, M.; MacLeod, A. M.; Sadowski, S.; Stevenson, G. I. Serine derived NK1 antagonists 2: a pharmacophore model for arylsulfonamide binding. Bioorg. Med. Chem. Lett. 1998, 8, 1851-1856.
14. Irie, O.; Iwasaki, G.; Masuya, K.; Miyake, T.; Teno, N. Preparation of spiro-substituted pyrrolopyrimidines as inhibitors of cathepsin S and/or cathepsin K. World Patent WO 2004076455, 2004.
15. Kumar, S.; Dare, L.; Vasko-Moser, J. A.; James, I. E.; Blake, S. M.; Rickard, D. J.; Hwang, S.-M.; Tomaszek, T.; Yamashita, D. S.; Marquis, R. W.; Oh, H.; Jeong, J. U.; Veber, D. F.; Gowen, M.; Lark, M. W.; Stroup, G. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007, 40, 122-131.
16. Stoch, S. A.; Wagner, J. A. Cathepsin K Inhibitors: A novel target for osteoporosis therapy. Clin. Pharmacol. Ther. 2008, 83, 172-176.
17. The dealkylated derivative 4 was found as the metabolite in the BM sample treated with 3.
18. Mundy, G.; Garrett, R.; Harris, S.; Chan, J.; Chen, D.; Rossini, G.; Boyce, B.; Zhao, M.; Gutierrez, M. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286, 1946-1949.
19. Edwards, C. J.; Hart, D. J.; Spector, T. D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000, 355, 2218-2219.